Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05230907 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1- PF-05230907 or Placebo | EXPERIMENTAL | - |
| Cohort 2- PF-05230907 or Placebo | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 1 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 2 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 3 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 4 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 5 | EXPERIMENTAL | - |
| PF-05230907 and Placebo Cohort 6 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-05230907 | DRUG | A single intravenous dose of 3 μg/kg |
| Placebo | DRUG | A single intravenous dose of matched placebo |
| Placebo for PF-05230907 | DRUG | 0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose |
Inclusion Criteria: * Healthy male of females * Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs) and \<120 kg (265 lbs). * Japanese subjects who have four biologic Japanese grandparents born in Japan. Exclusion Criteria: * Pregnant or nursing females. * Femal...
PF-05230907 is an investigational monoclonal antibody developed by Pfizer, Inc. It has been studied in Phase 1 clinical trials in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed, and no approved indication is associated with it.
PF-05230907 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored both Phase 1 trials of the antibody, one conducted in the United States and one in Belgium.
PF-05230907 is in Phase 1 development. Both of its clinical trials were Phase 1 studies in healthy volunteers, and both have been completed. No later-phase trials have been registered, and the antibody is not approved for any indication.
PF-05230907 has been evaluated in two completed Phase 1 trials. NCT01897142 tested safety, tolerability, pharmacokinetics and pharmacodynamics in 49 healthy volunteers in Belgium. NCT02537002 was a single-dose study in 17 healthy Japanese subjects in the United States. Together the trials enrolled 66 participants.
Both PF-05230907 trials were randomized, double-blind, and controlled, enrolling a total of 66 healthy adult volunteers aged 18 and older. NCT01897142 enrolled 49 participants in Belgium, and NCT02537002 enrolled 17 healthy Japanese subjects in the United States. Both studies are now completed.